Diffuse large B-cell lymphoma trials in South Korea

In South Korea 18 Also abroad 350

16 of 18 trials · From ClinicalTrials.gov, checked 15 November 2026. Ask the study team whether a trial fits you.

Phase 1Taking people
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Where
Daejeon, Seongnam, Seoul
Age
18 years and over
People
453 worldwide
Run by
Pfizer
See details and how to joinNCT03460977 · EU 2023-509179-18-00
Phase 3Taking people
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Where
Busan, Daejeon, Goyang-si, Seoul
Age
18 years and over
People
1,046 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06717347 · EU 2024-515566-13-00
Phase 2Active, not recruiting
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
Where
Seongnam-si, Seoul
Age
18 years and over
People
130 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06806033 · EU 2024-516791-15-00
Phase 3Taking people
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Where
Busan, Daegu, Incheon, Seoul, Suwon
Age
18 years and over
People
904 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT06091865 · EU 2022-502785-25-00
Phase 2/3Active, not recruiting
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Where
Seoul
Age
18 years and over
People
290 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT05139017 · EU 2022-502646-27-00
Phase 2Taking people
Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
Where
Busan, Daegu, Gyeongsangnam-do, Incheon, Jeonju, Seogu, Seoul, Suwon, Ulsan
Age
65 years to 99 years
People
80 worldwide
Run by
AstraZeneca
See details and how to joinNCT05952024
Phase 1/2Taking people
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Where
Seoul
Age
6 months to 25 years
People
90 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06395103 · EU 2023-507178-41-00
Phase 2Taking people
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Where
Goyang-si, Hwasun, Seogu, Seoul, Suwon
Age
18 years and over
People
250 worldwide
Run by
Allogene Therapeutics
See details and how to joinNCT06500273
Phase 1/2Taking people
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Where
GangnamGu, SeochoGu, SeodaemunGu, Seogu, Seoul, SongpaGu
Age
18 years and over
People
689 worldwide
Run by
BeOne Medicines
See details and how to joinNCT05006716 · EU 2022-502157-33-00
Phase 1/2Taking people
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Where
Daegu, Goyang-si, Incheon, Seoul
Age
18 years and over
People
300 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT04104776 · EU 2023-508002-20-00
Phase 1/2Taking people
Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients
Where
Seoul
Age
19 years and over
People
91
Run by
Curocell Inc.
See details and how to joinNCT04836507
Phase 2Taking people
Study of Lenalidomide/Rituximab Maintenance for Transplantation Ineligible Patients With PCNSL.
Where
Seoul
Age
19 years and over
People
30
Run by
Kim, Seok Jin
See details and how to joinNCT04627753
Phase 1/2Taking people
Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients
Where
Seoul
Age
19 years and over
People
98
Run by
TICAROS Co., Ltd.
See details and how to joinNCT07473167
Phase 2Taking people
Anbalcabtagene Autoleucel in Relapsed/Refractory CNS Lymphoma
Where
Seoul
Age
19 years and over
People
12
Run by
Hyungwoo Cho
See details and how to joinNCT07062627
Phase 1/2Not yet taking people in South Korea
Golcadomide, Poseltinib, and Rituximab for Relapsed/Refractory Diffuse Large B-cell Lymphoma
Where
Seoul
Age
19 years and over
People
20
Run by
Seoul National University Hospital
See details and how to joinNCT07269639
Phase 1/2Taking people
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
Where
Goyang, Incheon, Seoul
Age
18 years and over
People
84 worldwide
Run by
Kartos Therapeutics, Inc.
See details and how to joinNCT04502394